Pediatric Allergy Care & Diagnosis

Recurrent Sinusitis or Recurrent Rhinitis? Why Many “Sinus Attacks” Are Not Sinus Infections

Many patients use the term “sinus infection” to describe repeated episodes of nasal blockage, facial pressure, thick mucus and feeling unwell. The problem is that these symptoms do not automatically mean the sinuses are infected. A more accurate question is: Is this recurrent acute sinusitis, or is it recurrent acute rhinitis? That distinction matters. If the problem is recurrent acute rhinitis, then repeated antibiotics and limited sinus surgery are unlikely to help. If the problem is true recurrent acute sinusitis, then the pattern is usually more localised, more objective and more anatomically consistent. The nose and sinuses are connected, but they are not the same structure. The lining of the nose can become inflamed from viral infections, allergy, smoke, pollution, climate change or irritants. That can produce congestion, mucus and pressure. This is rhinitis. Sinusitis implies inflammation within the sinus cavities themselves, usually supported by endoscopy or CT findings that match the symptoms. This is why nasal congestion is not always the same as nasal obstruction , and why repeated congestion should not automatically be interpreted as recurrent bacterial sinus infection.

Bilateral symptoms usually mean inflammation, not bacterial sinusitis

The left and right sinus cavities are not a single shared cavity. They are separate anatomical systems. When both sides become congested at the same time, with bilateral pressure and mucus production, it is very unlikely that both sinus systems have simultaneously developed a primary bacterial infection or identical anatomical blockage. That pattern is much more consistent with a whole-nose inflammatory event. The common triggers are viral infection, allergic inflammation, irritant exposure, weather change, or a combination of these factors. This point is often missed. A patient may describe repeated episodes of “sinus” pressure, thick mucus and blockage. However, if the symptoms are synchronous and bilateral, the process is almost never a bacterial sinus infection. It is far more likely to be viral-allergic rhinitis, or a broader inflammatory reaction of the nasal lining.

Bactrial sinusitis is unilateral for most patients....not just prolonged symptoms Duration alone does not solve the problem. A rhinitis flare does not have to settle within a few days. Once the nasal lining is inflamed, the reaction can persist for weeks, in the same way that dermatitis can continue for weeks after a trigger has set it off. Under current rhinosinusitis definitions, disease is not called chronic until symptoms have persisted for 12 weeks or more. Therefore, an episode lasting two, three or four weeks is not automatically bacterial sinusitis. The pattern, laterality, endoscopy and imaging matter more than duration alone.

What true recurrent acute sinusitis usually looks like

True recurrent acute sinusitis is uncommon, but it does exist.

Bilateral congestion, mucus and pressure are more often inflammatory than bacterial. Unilateral disease is one feature that makes bacterial sinusitis more likely. The pattern is usually more convincing when episodes are: - repeatedly localised to the same side or the same sinus region - associated with lateralised facial pain or pressure rather than vague bilateral fullness - associated with objective findings during the episode, such as endoscopic inflammation or CT opacification in the relevant sinus - separated by near-normal or normal intervals between attacks - sometimes linked to a reproducible drainage problem, dental source, barosinusitis or local anatomical issue European guidance describes features that raise suspicion for acute bacterial rhinosinusitis, including fever, severe local pain, double worsening, raised inflammatory markers and unilateral disease. These features are quite different from repeated bilateral congestion, mucus and pressure during viral or allergic flares. True recurrent acute sinusitis is therefore a more localised and objective diagnosis. It should not be used as a default label for every recurrent nasal inflammatory event.

What the acute CT study showed

In a study of patients referred with suspected recurrent acute rhinosinusitis, the key question was simple: when these patients had their next “sinus attack,” would acute CT imaging actually show sinus disease? Most patients were convinced that their problem was sinusitis. Baseline CT scans were normal or near normal. Patients were then asked to return during an acute symptomatic episode for repeat assessment and imaging. The result was striking. Acute CT rarely confirmed true sinus disease. Only a very small proportion had objective changes consistent with recurrent acute rhinosinusitis. Most patients ultimately had rhinitis, headache/migraine or facial pain rather than recurrent sinus infection. This fits with clinical experience. A patient may feel pressure, congestion and mucus during an acute episode, but those symptoms can come from inflamed nasal mucosa, not infected sinus cavities.

Green or yellow mucus does not prove bacterial sinusitis

One of the most persistent myths is that green mucus means bacterial infection. It does not. Green or yellow mucus often reflects neutrophils and inflammatory proteins such as myeloperoxidase. Viral upper respiratory infections can produce thick, coloured mucus. Allergy can also make mucus production worse, especially when the nasal lining is already primed and reactive.

Green pigment from Iron-containing heme groups in myleoperoxidase accounts for the colour of mucus. Myleoperoxidase is 5% of the dry weight neutrophils and accumulate in the absence of bacterial infection. There is a 100-fold increase in neutrophils during a common cold. A simple example is a viral cold in an allergic patient. The allergy has already made the nasal lining swollen and irritable. Then the viral infection arrives. The combined effect can be far worse than either trigger alone. I often explain this to patients as pouring petrol on a fire. The virus is the spark. The allergic airway is the fuel. The result feels like “bad sinus,” but the mechanism is usually acute nasal inflammation, not bacterial sinus infection.

Why allergy makes viral events feel like sinusitis

Allergic rhinitis is not a trivial condition. Many patients adapt to a chronically inflamed nose and do not recognise their baseline allergy. They only notice the problem when a virus, weather shift or irritant exposure pushes the airway over its threshold. This is why some patients say: “Every cold goes to my sinuses.” Often, what is actually happening is: “Every cold causes a larger inflammatory rhinitis response because my nasal lining is already primed.” The same person may have mild background nasal congestion, intermittent sneezing, postnasal drip, itchy eyes or seasonal flares, but they do not think of themselves as allergic. Then a viral infection causes a much stronger reaction: congestion, pressure, mucus and fatigue. That episode is then labelled “sinusitis.”

Minor CT changes can be incidental

Another problem is over-reading minor CT changes. Small areas of mucosal thickening, small retention cysts or minimal sinus lining changes are common in people without sinus symptoms. These findings do not automatically explain facial pressure or recurrent congestion.

Minor mucosal changes are common in normal sinuses and not pathological nor predispose patients to recurrent sinusitis. A CT scan needs to be interpreted in context. The question is not, “Is there any mucosal thickening at all?” The real question is: Do the radiology, symptoms, endoscopy and timing all point to the same disease process? This is why ENT surgeons must review sinus CT scans, not just the report . A report may mention mucosal thickening, narrowing or anatomical variation, but those words do not prove that the finding is clinically meaningful. The scan needs to be reviewed against the patient’s symptom pattern. If the symptoms are bilateral and recurrent, but the scan is normal or only shows minor incidental change, limited sinus surgery is usually a low-value intervention. Surgery cannot reliably treat a whole-airway inflammatory problem if the sinus cavities are otherwise functioning.

Why antibiotics are often the wrong response

Antibiotics are still commonly prescribed for acute “sinus” episodes. Sometimes they are appropriate. But in many patients with recurrent bilateral congestion, mucus and pressure, antibiotics are treating the wrong disease. They may not improve the episode because the driver is viral or allergic inflammation. Repeated antibiotic use can also alter the microbiome, expose patients to adverse effects and reinforce the mistaken idea that every nasal inflammatory flare is bacterial sinusitis. A more useful approach is to define the episode more carefully: - Did symptoms start on one side or both sides? - Is there severe unilateral pain? - Is there fever? - Is there “double worsening,” where the patient improves then deteriorates again? - Does endoscopy or acute imaging show sinus inflammation that matches the symptoms? If the pattern is bilateral and synchronous, bacterial sinusitis should be considered unlikely unless there are unusually strong objective findings to suggest otherwise.

Treat the acute event as inflammation

If the episode is acute rhinitis, the treatment should focus on controlling inflammation quickly and effectively. This is where nasal treatment is often underused. In dermatology, general practitioners are familiar with treating acute dermatitis intensively for a short period, sometimes with frequent topical corticosteroid application and occlusion to improve absorption. The nose rarely gets the same practical treatment plan. For acute rhinitis flares, a short, focused period of intensive topical nasal therapy may be useful. Examples include combination corticosteroid and antihistamine sprays such as: - fluticasone plus azelastine - mometasone plus olopatadine

Combination INCS are most effective for short term intensive use These sprays treat both allergic and inflammatory components. They are not antibiotics. They need to be used correctly, with good technique, and some patients need an acute action plan rather than occasional under-dosing. Saline irrigation may also help by clearing mucus and reducing the burden of irritants. It is not a cure, but it can be useful during high mucus periods. The aim is not to “open blocked sinuses.” The aim is to settle the inflamed nasal lining.

Modify the predisposition: treat the allergic airway

There is also a longer-term strategy. If allergy is part of the problem, the goal should not only be to treat each flare after it occurs. The goal should also be to reduce the predisposition to large inflammatory flares. For some patients, that means allergen immunotherapy. Allergen immunotherapy is different from standard allergy medication. Antihistamines and nasal steroid sprays suppress symptoms while they are being used. Immunotherapy aims to change the immune response to the relevant allergen over time. This is particularly relevant for patients who are “fine most of the time” but have large nasal reactions when a viral infection, pollen season or weather change occurs. Their airway may be sitting close to its inflammatory threshold. A virus then pushes it over the edge. Treating the allergic component can reduce the background inflammatory load. It does not stop every virus, and it is not an acute rescue treatment. But in properly selected allergic patients, immunotherapy may reduce the tendency for viral and allergic triggers to combine into repeated severe nasal flares. This is why recurrent “sinus” episodes should prompt clinicians to ask whether the patient has undertreated allergic rhinitis. In many cases, the correct long-term plan is not sinus surgery. It is better allergy diagnosis, better rhinitis control and, in selected patients, early allergen immunotherapy in allergic rhinitis .

Prevention: reduce viral exposure and reduce airway reactivity

Prevention has two parts. The first is simple viral prevention. Respiratory viruses spread through contact and close exposure. Hand washing, avoiding touching the face during viral seasons, and practical hygiene around young children remain useful. This is especially relevant for parents of children in daycare or school, and for younger adults with high social exposure. The second is reducing baseline airway reactivity. If allergy is part of the problem, it needs to be treated properly. That may include regular intranasal therapy, allergen avoidance where practical, and in selected patients, allergen immunotherapy. A patient with an untreated allergic nose is more likely to experience exaggerated symptoms during viral infections. Treating the baseline allergic airway may reduce the size of the inflammatory response when the next virus arrives.

Where zinc fits

Zinc is relevant because many of these episodes are viral respiratory events, not bacterial sinus infections. Zinc has plausible biological effects in viral respiratory infections. It is involved in immune function and may interfere with viral binding or replication in some settings. The clinical evidence is not perfect, and it depends heavily on the form of zinc, dose, route and timing. A BMJ Open rapid systematic review of adults found some evidence that zinc may prevent acute viral respiratory tract infection symptoms and shorten symptom duration, but certainty was limited by bias, small samples and heterogeneity. A later Cochrane review was more conservative, finding little or no clear prevention benefit, possible shortening of cold duration when used for treatment, and more non-serious adverse events. The practical message is not that zinc is a cure for sinusitis. It is not. The more reasonable message is: For people with frequent viral-triggered nasal flares, maintaining adequate zinc intake may be one useful part of a prevention strategy. For Australian adults, the usual recommended dietary intake is 14 mg/day for men and 8 mg/day for women. The adult upper level is 40 mg/day from total intake. That matters because high-dose zinc, especially if used chronically, can cause nausea, gastrointestinal upset and copper deficiency.

Regular zinc supplementation can reduce acute respiratory events Short-term zinc lozenges used early in a cold are a different question from daily zinc supplementation. Some lozenge trials use higher doses for a limited number of days, but that is not the same as advising high-dose zinc every day for prevention. A practical approach is: - aim for adequate zinc intake through diet first - consider a modest supplement if dietary intake is likely to be low - avoid chronic zinc intake above the adult upper level unless medically supervised - avoid intranasal zinc products because of safety concerns around smell disturbance - be cautious with zinc if taking medications that interact with minerals, including some antibiotics Zinc should be presented as a supportive measure, not a replacement for accurate diagnosis.

When to suspect it really is sinusitis

A true sinusitis episode is more likely when there is a unilateral pattern, severe localised pain, fever, worsening after initial improvement, or persistent objective sinus inflammation on endoscopy or CT.

Endoscopy during the acute event confirms sinusitis on the patients left (B) and the normal right side for comparison (A) The diagnosis becomes less convincing when episodes are bilateral, synchronous, recurrent with viral or seasonal triggers, and associated with normal or near-normal CT scans between events. The key is not simply how long the symptoms last. Rhinitis events can last for weeks. The key is whether the pattern matches sinus disease.

Why surgery is low value in the setting of recurrent bilateral symptoms

Sinus surgery has a role when there is objective sinus disease and symptoms match the anatomy. It is not a general treatment for bilateral congestion, mucus and facial pressure in the setting of normal or near-normal sinus cavities. Operating on normal sinuses does not treat allergy, viral susceptibility, mucosal hyperreactivity or migraine. In these patients, surgery can create a short-lived “honeymoon” effect because postoperative care temporarily changes topical treatment and nasal airflow, but it does not address the real driver.

Why Immunotherapy Should Not Be the Last Step in Allergic Rhinitis

Allergic rhinitis is often treated as a symptom problem. A patient has sneezing, runny nose, itching, watery eyes or nasal congestion, so treatment is aimed at suppressing those symptoms. Intranasal corticosteroid sprays, antihistamines and leukotriene receptor antagonists can all be useful. For short-lived allergy, such as a few weeks of seasonal pollen symptoms, this approach is entirely reasonable. The problem is different when the allergy is chronic. House dust mite allergy is not a two-week problem. For many patients, it is a decade-long or lifelong inflammatory exposure. In that setting, simply suppressing the allergic response year after year with pharmacotherapy is not always a long-sighted strategy. It may control symptoms, but it does not meaningfully change the allergic disease process. This is where allergen immunotherapy deserves a different place in the treatment discussion.

Pharmacotherapy suppresses symptoms; immunotherapy modifies the disease

The conventional allergic rhinitis treatment ladder usually begins with pharmacotherapy. Patients are offered antihistamines, nasal steroid sprays, combination sprays or leukotriene antagonists. Immunotherapy is often considered later, when symptoms are severe, when multiple organs are involved, or when the patient has failed standard medical treatment. That sequence makes sense for some patients. It makes less sense for a teenager or young adult with clear house dust mite allergy, chronic nasal congestion and years of disease ahead. The distinction is simple: - Pharmacotherapy suppresses the allergic response while it is being used. - Allergen immunotherapy aims to change the immune response to the allergen. This does not mean immunotherapy is needed for every patient with allergic rhinitis. It does mean that for persistent house dust mite allergy, especially when nasal obstruction is chronic, immunotherapy should be discussed much earlier than it often is. The question should not simply be, “Can we suppress the symptoms?” The better question is, “What is the long-term plan for this allergic disease?”

Why house dust mite allergy is different

Seasonal allergic rhinitis can be episodic. A patient may have symptoms for a few weeks or months, then recover for the rest of the year. In that setting, using medication during the season is practical. House dust mite allergy is usually perennial. The exposure occurs in the bedroom, mattress, carpet, clothing and indoor environment. The patient is not simply reacting to an occasional allergen. They are living with a persistent allergic stimulus. That matters clinically because persistent allergic inflammation can produce more than sneezing and a runny nose. It can contribute to chronic nasal congestion — and nasal congestion is not always the same as nasal obstruction — turbinate swelling, middle turbinate oedema, sleep disturbance, mouth breathing and reduced quality of life.. A treatment strategy based only on symptom suppression may be too passive for that type of patient.

The evidence base for immunotherapy is not small

One reason immunotherapy is still under-discussed is that it is sometimes treated as a niche or late-stage option. That is difficult to justify from the evidence base. A recent network meta-analysis by Zhang and colleagues compared biologics, allergen immunotherapy and pharmacotherapies for moderate-to-severe allergic rhinitis. The analysis included 28 randomised controlled trials involving 13,312 participants. It compared biologics, allergen immunotherapy and key pharmacotherapies, including intranasal corticosteroids alone or in combination with antihistamines. For short-term nasal symptom control, biologics performed best. Anti-IL-4Rα therapy ranked highest for Total Nasal Symptom Score, followed by anti-IgE therapy. Allergen immunotherapy ranked below biologics but above all pharmacotherapies for nasal symptom control.

Foreest plots of comparative efficacy and safety for all interventions versus placebo in treating moderate-to-severe allergic rhinitis. (a) Mean difference in TNSS change from the baseline. (b) Mean difference in TOSS change from the baseline. (c) Mean difference in RQLQ change from the baseline. (d) Risk ratio in AE. CI, confidence interval; INAH, intranasal antihistamines; INCS, intranasal corticosteroids; OAH, oral antihistamines; RQLQ, Rhinitis Quality of Life Questionnaire; RR, risk ratio; TNSS, Total Nasal Symptom Score; TOSS, Total Ocular Symptom Score. That result needs to be interpreted correctly. Biologics are powerful targeted suppressive therapies. They may have a future role in severe, refractory or multi-system type 2 inflammatory disease. But for ordinary persistent allergic rhinitis, biologics are unlikely to become routine first-line treatment because of cost, access and the need for longer-term safety data in otherwise non-life-threatening allergic disease. Allergen immunotherapy occupies a different position. It is not merely another suppressive treatment. It is the treatment class directed at modifying the allergic mechanism itself. In the Zhang analysis, even within a short-term comparison window, immunotherapy outperformed pharmacotherapy for nasal symptoms. Its real value is likely greater than that short-term ranking suggests, because immunotherapy is intended to induce longer-term immune tolerance, not simply produce rapid symptom suppression. The broader allergy literature also supports the idea that immunotherapy is not just a “nose treatment”. In a Cochrane review of injection immunotherapy for asthma, 88 randomised trials were included. There were 42 trials of house dust mite immunotherapy, 27 pollen trials, 10 animal dander trials and additional mould, latex and multi-allergen trials. Immunotherapy significantly reduced asthma symptoms and medication use and improved bronchial hyper-reactivity. The review estimated that only three patients needed treatment to avoid one deterioration in asthma symptoms, and four needed treatment to avoid one patient requiring increased medication. The skin literature is more cautious, but still relevant to the broader allergic disease discussion. A Cochrane review of specific allergen immunotherapy for atopic eczema identified 12 randomised controlled trials involving 733 participants, most involving house dust mite allergy. The evidence was lower quality and the results were less consistent than in allergic rhinitis and asthma. Some investigator-rated outcomes improved, but participant-reported eczema outcomes were less convincing. This should not be overstated. Immunotherapy is not a universal solution for every atopic disease. But the existence of randomised trial evidence across rhinitis, asthma and eczema reinforces the larger point: immunotherapy is a serious disease-modifying strategy, not an alternative-health add-on. This is why patient surprise is understandable. Many patients with persistent allergic rhinitis ask, “Why wasn’t this discussed with me earlier?” For a patient with confirmed house dust mite allergy, chronic symptoms and years of expected disease, that is a fair question.

Oral tablets have changed the practicality of immunotherapy

Historically, immunotherapy was often thought of as injection therapy. Subcutaneous immunotherapy is effective, but it requires repeated injections, clinic attendance and post-injection monitoring. It also carries a risk of systemic allergic reactions, including rare severe reactions. Sublingual immunotherapy has changed the practical discussion. Modern house dust mite sublingual immunotherapy tablets or wafers use standardised allergen extracts and fixed dosing. They are placed under the tongue and are easier to initiate and continue than many older aqueous drop regimens. A 2026 meta-analysis comparing subcutaneous immunotherapy and sublingual immunotherapy in allergic rhinitis included six randomised controlled trials and 588 participants. It found no statistically significant difference in treatment discontinuation between subcutaneous and sublingual immunotherapy. However, adverse events were significantly higher with subcutaneous immunotherapy than with sublingual immunotherapy.

Evidence base for oral allergen immunotherapy in persistent allergic rhinitis, showing randomised controlled trials and systematic reviews supporting disease-modifying treatment. This does not prove that sublingual immunotherapy is more effective. It does suggest that, when efficacy is broadly comparable and convenience and safety matter, sublingual tablet therapy is a very reasonable starting point for many patients. That is particularly relevant in routine allergic rhinitis care. A teenager with chronic house dust mite allergic rhinitis is more likely to accept a daily sublingual wafer than repeated injection visits. If the goal is to start disease-modifying therapy early, the ease of use matters.

The patient journey is the missing part of the decision

The traditional question is: “Are the symptoms bad enough to justify immunotherapy?” That is the wrong question for many patients. A better question is: “Is this a chronic allergic disease that the patient is likely to manage for years or decades?” For persistent house dust mite allergy, the answer is often yes. If a 15-year-old has chronic nasal congestion, proven house dust mite sensitisation, clear allergic findings on examination and ongoing symptoms, then simply prescribing years of sprays and antihistamines may not be the most strategic plan. This is also where clinicians need to separate allergic mucosal disease from functional nasal obstruction, because the treatment strategy should follow the mechanism rather than the symptom label. A more useful treatment conversation is: - What is the allergic driver? - Is the allergen avoidable or persistent? - Is the patient likely to need treatment for months, years or decades? - Is the nose showing tissue effects of allergy, not just symptoms? - Would disease modification be more sensible than repeated suppression? - If pharmacotherapy is used, what is the review point and exit strategy? The last question is particularly important. Patients should not drift for years on partly effective medication without a plan.

Central compartment atopic disease shows why this matters

Central compartment atopic disease, or CCAD, is a good example of the problem. CCAD is an allergic tissue-remodelling condition affecting the central part of the nose, including the middle turbinate, superior septum, superior turbinate and uncinate region. It can be understood as part of a spectrum of inhalant allergy in which chronic exposure leads to visible mucosal change. These patients often have house dust mite sensitisation. They may have nasal obstruction, pressure symptoms, smell disturbance, sinus symptoms and polypoid central compartment change. By the time they require surgery, pharmacotherapy has usually already failed to prevent progression. That is why simply operating and then placing the patient back on the same pharmacotherapy that failed before surgery is conceptually weak. Surgery can remove obstructing tissue and improve sinus ventilation. It can reduce the burden of polypoid remodelling. But surgery does not switch off the inhalant allergy that drove the disease in the first place. In a retrospective cohort study of surgically treated, house dust mite-sensitised CCAD patients, 86 patients were assessed after surgery. All patients receiving allergen immunotherapy had started it before surgery. At 12 months, patients treated with immunotherapy had significantly less recurrent middle turbinate oedema than those not receiving immunotherapy: 15.6% versus 52.9% with diffuse or worse oedema. They also required less frequent topical corticosteroid irrigation: 37.5% versus 79.6% using corticosteroid irrigations four or more times per week. Symptoms were similar between the groups at 12 months, but the endoscopic and treatment-burden findings are the more important signal. Immunotherapy appeared to reduce allergic tissue activity and allowed de-escalation of pharmacotherapy. That is exactly the strategic point. If the disease process is allergic tissue remodelling, then postoperative care should not simply be more pharmacological suppression. It should include disease modification.

A more rational treatment strategy for persistent allergic rhinitis and CCAD

For persistent house dust mite allergic rhinitis, immunotherapy should sit at the centre of the long-term treatment strategy. Pharmacotherapy still has a role, but that role should be understood clearly. Nasal steroid sprays, antihistamines and other suppressive treatments are useful for short-term symptom control, especially during flares. These flares are common with viral upper respiratory tract infections, seasonal exposure changes, dust exposure, sleep disruption or other inflammatory triggers. But for chronic allergic disease, pharmacotherapy should not be the whole plan. A more rational approach is: - Confirm the allergic driver with history, examination and allergy testing. - Assess the nose objectively, including endoscopy and objective nasal airflow and allergy testing when symptoms are persistent, obstructive or not responding as expected. - Place allergen immunotherapy at the centre of the long-term strategy when house dust mite allergy is perennial and clinically relevant. - Use pharmacotherapy for short-term disease suppression, exacerbations and bridging while immunotherapy takes effect. - Consider sublingual tablet immunotherapy early for many patients because it is standardised, convenient and avoids the injection-related systemic reaction risk of subcutaneous therapy. - Consider surgery only when there is structural obstruction, turbinate hypertrophy or tissue remodelling that will not reverse with allergy treatment alone. This is the same broader principle discussed in “septal deviation and big turbinates” is not a diagnosis: surgery helps when it addresses the correct mechanism, but it is not a substitute for diagnosing and treating the underlying inflammatory driver. - After surgery for CCAD or allergic tissue remodelling, avoid returning the patient to the same failed pharmacotherapy-only strategy. This is particularly relevant for teenagers and young adults. A chronic dust mite allergic nose at age 15 is not a short-term medication problem. It is a long-term airway management problem.

Why this should be discussed early

There is no good reason for a patient with persistent allergic rhinitis to learn about immunotherapy only after years of sprays, antihistamines and frustration. The threshold for discussing immunotherapy should be low when: - symptoms are perennial rather than seasonal - house dust mite sensitisation is clear - nasal congestion is chronic - the patient is young and likely to live with the disease for decades - there is asthma, eczema, conjunctivitis or broader atopic disease - endoscopy shows allergic tissue effects such as middle turbinate oedema - pharmacotherapy is needed continuously rather than intermittently - surgery is being considered for allergic tissue remodelling Discussing immunotherapy is not the same as forcing it on every patient. It is giving the patient a proper long-term framework. If immunotherapy has level 1 evidence in allergic rhinitis and asthma, if modern sublingual preparations are standardised and practical, and if persistent house dust mite allergy is a long-term disease, then immunotherapy should be raised early. It is hard to justify otherwise.

Conclusion

Allergic rhinitis should not always be treated as a short-term symptom disorder. For seasonal symptoms, pharmacotherapy is often sensible and sufficient. For persistent house dust mite allergy, the thinking should be different. Pharmacotherapy suppresses symptoms. It has value during exacerbations, viral upper respiratory flares and short-term symptom deterioration. But it does not alter the allergic immune response in the same way as allergen immunotherapy. The recent comparative evidence shows that allergen immunotherapy performs better than pharmacotherapy for nasal symptom control in moderate-to-severe allergic rhinitis, while biologics offer the strongest short-term suppression but are unlikely to be routine therapy for simple allergic rhinitis. Cochrane data in asthma show a substantial randomised trial evidence base for immunotherapy improving symptoms, medication use and bronchial hyper-reactivity. Direct comparison data in allergic rhinitis suggest sublingual immunotherapy has practical safety advantages over subcutaneous immunotherapy, with no clear disadvantage in treatment discontinuation. That matters most when the allergic burden is measured in decades, not weeks. In patients with chronic house dust mite allergy, persistent congestion or allergic tissue remodelling, immunotherapy should not be reserved only for the end of the treatment pathway. It should be discussed early as part of a long-term strategy. The goal should not be indefinite suppression of allergy. The goal should be to change the allergic trajectory.

References

When the nose feels blocked but the airway is open: functional nasal obstruction and low-value nasal surgery

A common referral in tertiary rhinology is the patient who says: “I am a mouth breather,” “I never get enough oxygen,” or “my nose is ruining my sleep and energy.” Sometimes that patient has obvious nasal obstruction: a severe septal deviation, enlarged inferior turbinates, nasal polyps, allergic rhinitis or nasal valve collapse. In that setting, treatment can be high value.

But sometimes the nasal airway is already open.

The examination is unremarkable. The nose looks patent on endoscopy. Objective airflow testing is normal or near normal. The patient’s main concern is not really a blocked nostril, but fatigue, poor sleep, low energy, breathlessness, anxiety about breathing, or a general sense of not getting enough air.

That is a different clinical problem.

The nose filters, warms, humidifies and senses airflow. It is important for comfort, smell, airway protection and perceived sleep quality. But the nose does not oxygenate the blood. Gas exchange occurs in the lungs. Widening an already adequate nasal airway is unlikely to fix tiredness, poor energy, unexplained breathlessness or the feeling of “not getting enough oxygen.”

This is where Ray’s Rules become useful.

The turbinates are dynamic, not fixed

The inferior turbinates are vascular organs. They are not simply “large” or “small.” Their size changes through the day depending on posture, autonomic tone, allergy, rhinitis, irritants, infection, medication use and the normal nasal cycle.

Two normal physiological processes are especially important.

The first is the nasal cycle. This is the spontaneous alternating congestion and decongestion of the nasal mucosa. One side of the nose becomes more congested while the other side opens. This is driven by dilation and constriction of venous cavernous tissue in the turbinates and septum. Approximately 70–80% of healthy adults demonstrate a nasal cycle, although the pattern is not always perfectly regular or symmetrical. The cycle length may vary from 30 minutes to several hours.¹

The second is postural congestion. When a person moves from sitting upright to lying flat, central venous pressure may increase by up to approximately 8 mmHg because of hydrostatic pressure. This increases congestion of the nasal mucosa and nasal airway resistance. The effect is often greater when lying on one side, where the lower, dependent nasal cavity becomes more congested.¹,²

These normal physiological changes are amplified when the nasal lining is already inflamed or vascularly reactive, as occurs in allergic rhinitis, non-allergic rhinitis and inferior turbinate hypertrophy.

This explains why patients with true turbinate-driven obstruction often say:

“It swaps sides.” “It is worse when I lie down.” “It blocks on the side I sleep on.” “A decongestant spray opens it clearly.”

That history is not incidental. It is diagnostic information.

Ray’s Rules: a practical test of turbinate physiology

Ray’s Rules are a simple clinical heuristic for deciding whether a patient’s symptoms behave like vascular turbinate obstruction.

They ask whether the patient has:

Cycling nasal congestion — the blocked side changes from side to side. Postural congestion — the nose blocks when lying flat or on the dependent side. A clear response to topical decongestant — the airway improves when the vascular turbinate component is temporarily reduced.

These features suggest that the patient has an intact sensory perception of nasal airflow and a dynamic turbinate component to their obstruction. In other words, the symptoms behave like turbinate disease.³,⁴

This does not mean that every patient with positive Ray’s Rules needs surgery. Many still need medical management first: saline irrigation, intranasal corticosteroids, antihistamines, allergen avoidance, immunotherapy where appropriate, and treatment of rhinitis. But if symptoms persist despite well-conducted medical therapy, and the examination confirms inferior turbinate hypertrophy, turbinate reduction may be a rational intervention.

The important point is the reverse: patients who do not demonstrate these features may be poor candidates for turbinate surgery, particularly when objective findings are mild.

Ray's rules provide a simple pathophysioology linked screen for patients likely to benefit from turbinate reduction

When nasal surgery is more likely to be high value

Nasal surgery is more likely to be high value when there is a match between the patient’s symptoms, examination and objective findings.

For example, a patient with visible inferior turbinate hypertrophy, alternating nasal obstruction, night-time postural blockage and a strong response to decongestant has a plausible vascular turbinate problem. If medical treatment fails, turbinate reduction may address the mechanism of obstruction.

Similarly, a patient with a clear anterior septal deviation, nasal valve compromise, or fixed unilateral obstruction has a structural problem that may be improved by septoplasty, septorhinoplasty or valve surgery.

In both settings, the treatment target is clear: improve nasal airflow through a mechanically or physiologically obstructed nasal airway.

When nasal surgery may be low value

Surgery becomes low value when the patient’s main symptoms are not actually explained by the nose.

A common example is the patient who presents with “nasal congestion” but, on closer questioning, is primarily concerned about:

poor sleep waking unrefreshed fatigue low daytime energy reduced exercise tolerance breathlessness feeling they are “not getting enough oxygen” anxiety around breathing a general belief that mouth breathing is damaging their health

Many of these patients have become more aware of nasal breathing through popular health culture. Books such as James Nestor’s Breath: The New Science of a Lost Art have brought attention to nasal breathing, slow breathing, mouth breathing, breathwork and the relationship between breathing habits and health.⁵ This public discussion has been useful in many respects. Nasal breathing is physiologically preferable to chronic mouth breathing. It filters and humidifies air, supports nasal airflow sensation, and contributes to airway comfort.

But the popular message can become distorted. Some patients begin to attribute almost every symptom — fatigue, poor sleep, reduced concentration, exercise limitation, anxiety or “low oxygen” — to minor nasal findings. That is not good medicine.

If the nasal airway is open, airflow testing is normal, and the patient does not describe cycling congestion, postural congestion or decongestant response, then turbinate surgery is unlikely to solve the true problem. In that situation, it is more useful to look for other contributors: sleep apnoea, insomnia, stress, anxiety, poor sleep routine, medication effects, cardiopulmonary disease, anaemia, endocrine issues, deconditioning or broader health factors.

Telling the patient that nasal surgery is not indicated is not dismissive. It may be the most honest and protective answer.

Nasal breathing and sleep: important, but not magic

There is good evidence that treating nasal disease can improve subjective sleep quality. A systematic review and meta-analysis of allergic rhinitis and nasal septal deviation found that treatment improved patient-reported sleep measures, including Epworth Sleepiness Scale and Pittsburgh Sleep Quality Index scores.⁶

However, the same review found insufficient evidence that objective sleep metrics improve in the same way.⁶ This distinction matters.

A patient may feel that sleep is better after nasal treatment. That is a valid outcome. Better nasal airflow can reduce discomfort, reduce mouth breathing, improve CPAP tolerance in selected patients, and improve sleep-related quality of life. But improvement in nasal airflow sensation is not the same as better sleep function.

But nasal surgery should not be presented as a reliable treatment for objective sleep architecture, oxygenation, sleep apnoea or global fatigue unless the broader sleep disorder has been properly assessed. The nose contributes to sleep comfort. It is not the whole sleep system.

Functional nasal obstruction and unrealistic expectations

The most difficult group is the patient with severe symptoms, minimal objective obstruction and high expectations of benefit from surgery.

Some patients describe nasal obstruction in a way that resembles breathlessness, air hunger or anxiety about breathing. In the empty nose syndrome and functional nasal obstruction literature, this mismatch between symptoms and objective findings has become increasingly important. Patients may present before surgery with nasal airflow symptoms that are not explained by anatomy, then remain symptomatic or worsen after a technically adequate septal or turbinate procedure.³,⁴

This does not mean the symptoms are fake. It means the mechanism may not be surgically correctable.

In this setting, further surgery can be harmful. It may reinforce the belief that the problem is purely structural, create disappointment when the expected gains in sleep or energy do not occur, and expose the patient to the risks of an operation without a realistic chance of solving the primary complaint.

Ray’s Rules help identify the patient whose symptoms behave like turbinate physiology. They also help identify the patient in whom turbinate surgery may be the wrong tool. A terrific summary article by Professor Sacks is availiable here.

Why the profession needs to own this problem

Functional nasal surgery is under increasing scrutiny. In 2025, ENT UK expressed concern about South-East England ICB decisions to suspend funding for septoplasty, turbinate surgery and functional septorhinoplasty.⁷ Media coverage reported that some patients would receive NHS septoplasty funding only in exceptional circumstances.⁸

Blunt funding restrictions are not the right way to manage nasal obstruction. Some patients have severe, genuine, surgically correctable nasal airway disease. They need access to high-value nasal surgery.

But the profession also needs to be clear about where surgery is less likely to help. If surgeons do not define high-value nasal surgery carefully, funders may define it crudely.

A simple heuristic of “failed nasal steroid spray, therefore septoplasty and turbinate reduction” is not enough. Good decision-making should include the patient’s symptom pattern, endoscopy, objective airflow assessment where appropriate, response to decongestant, allergy/rhinitis evaluation and the patient’s expectations of benefit.

The practical message

Ray’s Rules are not a formal score. They are a practical clinical safeguard.

If the nose blocks from side to side, worsens with posture, and opens with decongestant, the symptoms are behaving like turbinate physiology. If examination confirms turbinate hypertrophy and medical therapy has failed, turbinate surgery may be a reasonable high-value intervention.

If the patient’s main concern is sleep, fatigue, tiredness, breathlessness or not getting enough oxygen, and the nasal airway is objectively adequate, nasal surgery is unlikely to solve the real problem.

A good rhinologist does not just widen noses. A good rhinologist decides when widening the nose is likely to help — and when it is not.

References

Pendolino AL, Lund VJ, Nardello E, Ottaviano G. The nasal cycle: a comprehensive review. Rhinology Online. 2018;1:67–76. doi:10.4193/RHINOL/18.021. Harvey RJ, Roland LT, Schlosser RJ, Pfaar O. Chief Complaint: Nasal Congestion. J Allergy Clin Immunol Pract. 2024;12(6):1462–1471. doi:10.1016/j.jaip.2024.04.028. Kanjanawasee D, Campbell RG, Rimmer J, Alvarado R, Kanjanaumporn J, Snidvongs K, Kalish L, Harvey RJ, Sacks R. Empty nose syndrome pathophysiology: a systematic review. Otolaryngol Head Neck Surg. 2022;167(3):434–451. doi:10.1177/01945998211052919. Png LH, Kalish L, Sacks R. Empty nose syndrome: the case for “functional nasal obstruction” as a predisposing risk prior to nasal surgery. Curr Otorhinolaryngol Rep. 2023;11:422–429. doi:10.1007/s40136-023-00487-w. Nestor J. Breath: The New Science of a Lost Art. New York: Riverhead Books; 2020. Fried J, Yuen E, Zhang K, Li A, Rowan NR, Schlosser RJ, Nguyen SA, Gudis DA. Impact of treatment for nasal cavity disorders on sleep quality: systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2022;166(4):633–642. doi:10.1177/01945998211029527. ENT UK. Statement concerning the suspension of funding for functional nasal surgery. Published 10 October 2025. Tapper J. NHS cuts will “severely impact” those who struggle to breathe. The Observer. Published 6 October 2025

FAQ

What is functional nasal obstruction?

Functional nasal obstruction describes a situation where a patient feels significantly blocked, but the nasal airway is open or near normal on examination and objective testing. The symptom is real, but the mechanism may not be a surgically correctable narrowing of the nose.

What are Ray’s Rules?

Ray’s Rules are a practical rhinology heuristic used to identify whether symptoms behave like turbinate-driven obstruction. The three features are cycling nasal congestion, postural congestion and a clear response to topical nasal decongestant.

What is cycling nasal congestion?

Cycling nasal congestion means the blocked side changes from one side of the nose to the other. This often reflects the normal nasal cycle, where one side of the nose becomes more congested while the other side opens.

What is postural nasal congestion?

Postural nasal congestion is nasal blockage that worsens when lying flat or lying on one side. It occurs because venous pressure and vascular congestion increase in the nasal lining, especially around the inferior turbinates.

Does a blocked nose cause low oxygen levels?

Usually no. The nose filters, warms, humidifies and senses airflow, but gas exchange occurs in the lungs. A blocked nose can affect comfort, perceived sleep quality and mouth breathing, but persistent breathlessness or concern about oxygen levels should be assessed beyond the nose.

Can nasal surgery improve sleep?

Nasal surgery and rhinitis treatment can improve patient-reported sleep quality in selected patients. However, evidence that nasal surgery reliably improves objective sleep measurements, sleep architecture or oxygenation is limited.

When is turbinate surgery more likely to help?

Turbinate surgery is more likely to help when symptoms behave like turbinate physiology: the blockage cycles from side to side, worsens with posture, improves with decongestant, and examination confirms inferior turbinate hypertrophy.

When is nasal surgery less likely to help?

“Septal deviation and big turbinates” is not a diagnosis: why nasal obstruction often returns after surgery

One of the commonest referral patterns I see as a tertiary rhinologist is the patient who has had nasal surgery, initially felt better, and then slowly developed the same sense of nasal blockage again. These patients often arrive disappointed, sometimes angry, and usually confused. They have been told they had a “septal deviation and big turbinates”, underwent septoplasty, turbinate reduction or both, and expected a durable solution.

The problem is that “septal deviation and enlarged turbinates” is not a diagnosis. It is a description of anatomy.

That distinction matters. A diagnosis should explain why the nose feels blocked, why the problem developed, why it behaves the way it does, and why a particular treatment should work. A deviated septum may explain unilateral nasal obstruction, particularly if it follows trauma or has been present since adolescence. But it is a weaker explanation for progressive, bilateral nasal congestion that has developed over time without injury.

When the obstruction is generalised, alternates from side to side, worsens when lying flat, or is clearly affected by irritants, seasons or indoor environments, the cause is usually more than fixed anatomy. It is often rhinitis. The next question should be: what type of rhinitis, and what is driving it?

Congestion and obstruction are not always the same thing

Patients and clinicians often use the same words differently. Patients may use “congestion” to mean blocked airflow, pressure in the face, mucus in the throat, heaviness in the head or even headache. In contrast, rhinologists usually reserve “obstruction” for impaired nasal airflow and “congestion” for mucosal swelling or vascular engorgement.

This mismatch has been formally described. In a study of how patients and clinicians define “nasal congestion”, patients were much more likely than clinicians to include pressure-related symptoms, mucus-related symptoms and other non-obstructive symptoms in their definition of congestion. This is why a patient can have a scan report mentioning a deviated septum or turbinate hypertrophy and still not have a useful diagnosis. The finding may be real, but it may not be the dominant cause of the symptom.

This issue is also central to our forthcoming Medicine Today feature article, How we breathe: Nasal congestion and treatment strategies, selected as the May feature article. The article emphasises that nasal congestion is more than a blocked nose: patient perceptions of pressure, mucus and airflow often diverge from clinical definitions, complicating diagnosis and management.

A practical distinction is this: a fixed anatomical obstruction tends to be consistent, often affecting one side more than the other, and may relate to trauma, nasal development, prior rhinoplasty or valve collapse. A physiological or inflammatory obstruction tends to vary. It may cycle from side to side, worsen when lying down, respond temporarily to decongestant spray, fluctuate with allergen exposure, or worsen in certain environments.

The second pattern is commonly turbinate-based and vascular, but the driver is often inflammatory, allergic, neurogenic or irritant-related rather than simply “large turbinates”.

The nose is not just a pipe

A simple but misleading model is that nasal breathing improves if the surgeon makes a larger tunnel. That is only partly true.

Humans do not directly “measure” airflow through mechanical airflow receptors in the nose. The sensation of clear nasal breathing is strongly influenced by cooling of the nasal lining as air passes across the mucosa. Trigeminal cold receptors, including TRPM8 receptors, help generate the perception of nasal patency. This explains why menthol, eucalyptus or similar products can make the nose feel clearer without objectively increasing airflow.

The nose on the left is not affected by allergy and has normal mucosa. The patient on the right has normal airflow but feels congested due the rhinitis reaction.

It also explains why surgery that creates space but does not restore healthy airflow over responsive mucosa may not solve the patient’s perceived congestion. Inflamed mucosa, thick mucus, vascular engorgement and tissue remodelling can all reduce the cooling signal. The patient may feel blocked even when the airway is not severely narrowed.

Conversely, after turbinate surgery, the early mechanical improvement may be obvious. But if the allergic or inflammatory drive persists, mucosal swelling and tissue remodelling can return.

The common mistake: treating the consequence, not the disease

Inferior turbinate hypertrophy is often the visible consequence of a long-standing mucosal disease. In allergic rhinitis, repeated allergen exposure can produce chronic inflammation, venous engorgement, glandular change and tissue remodelling. The turbinate becomes the visible structure that attracts surgical attention, but the allergy is the engine that keeps driving the process.

This is especially relevant in patients who do not present with classic “hay fever”. Many allergic patients do not volunteer itch, sneeze, watery rhinorrhoea or conjunctivitis. Their dominant symptom is obstruction. They may not intuitively think of allergy, and if the clinician does not test or examine for it, the disease is missed.

A more accurate formulation for many of these patients is not “septal deviation and big turbinates”. It is closer to:

Persistent rhinitis, often allergic or locally allergic, with turbinate and septal swell body tissue remodelling producing dynamic bilateral nasal obstruction.

That diagnosis leads to a different treatment plan.......not just surgery.

A negative allergy test does not always exclude allergy in the nose

Skin-prick testing and serum-specific IgE testing are important, but they are not perfect reflections of what is happening in the nasal mucosa. Some patients have negative skin and blood allergy tests but still react to allergen challenge directly in the nose. This is known as local allergic rhinitis.

Although epicutaneous tests for allergy are the gold standard, many patients with clear allergic rhinitis will have negative skin and serum tests. This doesnt mean that they dont have allergy, its just not present in surrogate markers for allergy in the nose. It can be as high 30%.

The concept is often referred to as “entopy” — allergy localised to the target organ rather than detectable systemically. A useful Australian shout-out belongs to Professor Simon Carney, whose work helped establish the idea that patients could show evidence of allergy in the absence of conventional systemic atopy. The term “entopy” was later used in the local allergy paradigm literature to describe this nose-localised allergic response.

This matters clinically. If a patient has a strongly allergic history — for example, seasonal symptoms, indoor dust mite pattern, morning congestion, turbinate oedema or mucus changes on endoscopy — a negative skin or serum test should not automatically close the door on allergy.

Hamizan and colleagues systematically reviewed nasal allergen provocation testing in allergic and non-allergic rhinitis. Across 46 studies, nasal allergen reactivity was present in 86.3% of patients classified as allergic rhinitis by systemic testing, but also in 24.7% of patients classified as non-allergic rhinitis. The authors concluded that local allergen reactivity is demonstrated in about one quarter of patients previously considered non-allergic.

That finding is not academic hair-splitting. It changes how patients should be treated. A patient labelled “non-allergic” may still have an allergic reaction in the nose and may still be suitable for allergy-directed therapies.

Why turbinate surgery can feel good — then fade

Turbinate reduction can be very effective. It creates space, reduces vascular tissue volume, and can improve nasal airflow. The issue is not that turbinate surgery is poor surgery. The issue is that it is often being asked to do the wrong job.

Surgery can reduce the tissue burden. It does not, by itself, switch off the allergic or inflammatory process that enlarged the tissue in the first place.

The long-term data are important here. De Corso and colleagues prospectively followed 305 patients with rhinitis who underwent radiofrequency volumetric inferior turbinate reduction. Early results were favourable, with significant improvement in nasal stuffiness, nasal obstruction and mouth breathing. But symptoms worsened after 36 months, with progressive recurrence, especially in allergic patients.

The relapse-free probability is the key figure. In the whole cohort, the cumulative probability of remaining relapse-free was 0.848 at 36 months but fell to 0.531 at 60 months. In allergic patients, it fell from 0.807 at 36 months to 0.357 at 60 months. In plain terms, the benefit was real, but it diminished over time, and allergic rhinitis was associated with worse durability.

This does not mean turbinate surgery “failed”. It means the underlying biology kept operating.

The diminshing effects of a simple turbinate procedure over time (De Corso E, Bastanza G, Di Donfrancesco V, Guidi ML, Morelli Sbarra G, Passali GC, et al. Radiofrequency volumetric inferior turbinate reduction: long-term clinical results. Acta Otorhinolaryngol Ital. 2016;36(3):199-205.)

A later systematic review of surgical interventions for inferior turbinate hypertrophy also supports the general effectiveness of turbinate surgery, showing meaningful improvements in subjective nasal obstruction and objective airflow measures across multiple techniques. But this should not be interpreted as a licence to label every bilateral blocked nose as a turbinate problem. The better conclusion is that turbinate surgery works best when the turbinate is genuinely the limiting structure and the disease process driving turbinate swelling has been identified.

This is the clinical pattern patients often describe: “It worked at first, then slowly stopped working.”

That slow loss of benefit should not automatically be interpreted as poor surgical technique. In many cases, the real problem is that the underlying rhinitis was never properly diagnosed, treated or modified.

Why intranasal steroid failure does not prove the problem is surgical

Another common heuristic is: try a nasal steroid spray; if it does not work, diagnose septal deviation and enlarged turbinates; then operate.

That is too simplistic.

A failed nasal spray trial does not prove that anatomy is the primary cause. It may mean the spray was poorly delivered, poorly adhered to, not strong enough, not the right treatment for the mechanism, or introduced too late to reverse established tissue remodelling. Or simply the initial benefit is not in align with patient expectations.

But patients with normal airflow on testing are the greatest risk from low benefit from septal and turbinate surgery in particular.

In persistent allergic rhinitis, especially house dust mite–driven disease, the relevant question is often not “did a spray help?” but “is this a chronic allergic airway disease requiring disease modification?”

Allergen immunotherapy is fundamentally different from symptom suppression. Antihistamines and intranasal corticosteroids may reduce symptoms while being used. Immunotherapy aims to reduce the immune response to the allergen itself. That is why, in selected patients, it should be considered earlier rather than after years of progressive tissue change.

This does not mean every patient needs immunotherapy. It means the diagnosis should be made properly before surgery is offered as the next step.

The pattern that should make clinicians pause

A simple septal deviation can explain unilateral obstruction. A single-sided blocked nose after trauma is a different problem from a patient who says:

“My nose blocks on both sides.”

“It changes sides.”

“It is worse lying flat.”

“It is worse overnight or in the morning.”

“It improves briefly with decongestant spray.”

“It has slowly developed over years.”

“I never had trauma.”

“I had turbinate surgery and it helped for a while, then wore off.”

That pattern should trigger a rhinitis workup, not just an anatomical label.

Assessment may include nasal endoscopy, allergy testing, objective airflow testing where available, decongestant response, and careful separation of airflow symptoms from pressure, mucus, sleep, fatigue and anxiety-related breathing concerns.

Rhinomanometry and nasal peak inspiratory flow can be useful because they test whether obstruction is truly airflow-related and whether it is reversible. This matters before offering more surgery to a patient whose main symptom may not be mechanical obstruction.

Surgery still has a role — but it must be integrated

The correct conclusion is not “avoid turbinate surgery”. That would be just another simplistic rule.

Turbinate surgery can be valuable when tissue remodelling has become a major contributor to obstruction. In some patients, immunotherapy or pharmacotherapy improves the inflammatory component, but the remodeled turbinate or septal swell body remains too bulky. In those patients, surgery can restore airflow while disease-modifying therapy reduces the risk of the same process recurring.

This is also why the sequence of care matters. A patient who has substantial allergic inflammation and turbinate remodelling may need both disease modification and anatomical optimisation. Surgery may improve the airway, but immunotherapy or other medical strategies may be needed to prevent the same mucosal process from continuing.

The better model is integrated treatment:

First, define the symptom: airflow obstruction, congestion, pressure, mucus or mixed symptoms.

Second, identify the mechanism: fixed anatomy, allergic rhinitis, local allergic rhinitis, nasal hyperreactivity, irritant exposure, medication effect, rhinitis medicamentosa, chronic rhinosinusitis or a functional overlay (anxiety/hyperventilation/panic disorder/SSD).

Third, match treatment to mechanism: immunotherapy for relevant allergic drivers, pharmacotherapy for symptom control, irritant cessation where relevant, and surgery where anatomy or tissue remodelling is genuinely limiting airflow.

This is particularly important for patients who have already had “low-value” nasal surgery. Many are not wrong about their symptoms. They are wrong about the explanation they were given — or the explanation was incomplete.

The key message

“Septal deviation and enlarged turbinates” is a finding. “Congested nose” is a symptom. Neither is a proper diagnosis.

When patients have progressive bilateral nasal obstruction, alternating congestion, postural blockage or loss of surgical benefit over time, the clinician should look beyond anatomy. The question is not simply whether the septum is bent or the turbinates are large. The question is why the nasal airway is behaving that way.

In many patients, the answer is rhinitis — often allergic rhinitis or local allergic rhinitis — with turbinate-based vascular congestion and tissue remodelling. Surgery may still help, but only if it is used as part of a broader plan that addresses the disease process driving the obstruction.

Patients do better when treatment is directed at the cause, not the label.

References

McCoul ED, Mohammed AE, Debbaneh PM, Carratola M, Patel AS. Differences in the intended meaning of congestion between patients and clinicians. JAMA Otolaryngol Head Neck Surg. 2019;145(7):634-640. doi:10.1001/jamaoto.2019.1073 Harvey RJ, Roland LT, Schlosser RJ, Pfaar O. Chief complaint: nasal congestion. J Allergy Clin Immunol Pract. 2024;12(6):1462-1471. doi:10.1016/j.jaip.2024.04.028 Sozansky J, Houser SM. The physiological mechanism for sensing nasal airflow: a literature review. Int Forum Allergy Rhinol. 2014;4(10):834-838. doi:10.1002/alr.21368 Carney AS, Powe DG, Huskisson RS, Jones NS. Atypical nasal challenges in patients with idiopathic rhinitis: more evidence for the existence of allergy in the absence of atopy? Clin Exp Allergy. 2002;32(10):1436-1440. doi:10.1046/j.1365-2745.2002.01494.x Powe DG, Bonnin AJ, Jones NS. ‘Entopy’: local allergy paradigm. Clin Exp Allergy. 2010;40(7):987-997. doi:10.1111/j.1365-2222.2010.03536.x Hamizan AW, Rimmer J, Alvarado R, Sewell WA, Kalish L, Sacks R, Harvey RJ. Positive allergen reaction in allergic and nonallergic rhinitis: a systematic review. Int Forum Allergy Rhinol. 2017;7(9):868-877. doi:10.1002/alr.21988 De Corso E, Bastanza G, Di Donfrancesco V, Guidi ML, Morelli Sbarra G, Passali GC, Poscia A, de Waure C, Paludetti G, Galli J. Radiofrequency volumetric inferior turbinate reduction: long-term clinical results. Acta Otorhinolaryngol Ital. 2016;36(3):199-205. doi:10.14639/0392-100X-964 Zhang K, Pipaliya RM, Miglani A, Nguyen SA, Schlosser RJ. Systematic review of surgical interventions for inferior turbinate hypertrophy. Am J Rhinol Allergy. 2023;37(1):110-122. doi:10.1177/19458924221134555 Chin D, Marcells G, Malek J, Pratt E, Sacks R, Harvey RJ. Nasal peak inspiratory flow as a diagnostic tool for differentiating decongestable from structural nasal obstruction. Rhinology. 2014;52(2):116-121. doi:10.4193/Rhino13.123

FAQ

Is a deviated septum always the cause of nasal obstruction?

No. A deviated septum can cause nasal obstruction, especially when symptoms are one-sided or followed nasal trauma. Progressive bilateral nasal congestion is often driven by rhinitis, allergy, turbinate swelling, nasal hyperreactivity or mucosal inflammation rather than septal anatomy alone.

Why did my turbinate surgery work at first and then stop working?

Expert Solutions for Ear, Nose, and Throat Problems